The magnitude of the reduction in prostate cancer deaths from population-based PSA screening is too small for a clinical and public health benefit. PSA screening of the general male population ...

Prostate cancer is the most common form of cancer among men in England, with cases surging by 25 per cent between 2019 and 2023, according to NHS data. It’s also the second-deadliest form of the ...

The understanding of prostate cancer has significantly evolved in the past 15 years. Therefore, many people — including primary care providers — may not be aware of the current guidelines for prostate ...

Extended follow-up data from the ProtecT trial highlight the importance of weighing the risks associated with radical treatment versus active surveillance for newly diagnosed localized prostate cancer ...

Celebrities have sent prostate cancer’s public profile soaring in recent years. But with accusations that some men are being ...

Follow-up overall survival, months, median (range) 96 (15-120) Follow-up PSA to recurrence or death, months, median (range) 55 (11-111) Follow-up PSA patients alive and recurrence-free, months, median ...

Dr. Barry W. Goy explains how to interpret PSA levels after prostate cancer treatment and how to manage recurrence based on disease progression. Among patients with intermediate-risk prostate cancer, ...